Therapy for relapsed MCL patients primarily revolves around the use of BTK inhibitors such as ibrutinib [68] (Table 1), or acalabrutinib (which has greater selectivity and fewer off-target effects compared to ibrutinib) [69]. The gene discussed is BTK; the disease is mantle cell lymphoma.